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Multicenter Phase II Trial of Motexafin Gadolinium and
Pemetrexed for Second-Line Treatment in Patients with
Non-small Cell Lung Cancer
Martin J. Edelman, MD,* Gregory Otterson, MD,† Joseph Leach, MD,‡ Thomas Malpass, MD,§
Ravi Salgia, MD, Dennie Jones, MD,¶ Tarak D. Mody, MD,# and Ramaswamy Govindan, MD**
Background: Motexafin gadolinium (MGd) disrupts redox-depen-
dent pathways by inhibiting oxidative stress-related proteins leading
to apoptosis. MGd selectively targets tumor cells, disrupting energy
metabolism and repair mechanisms, rendering cells more prone to
apoptosis. Preclinical studies with MGd and pemetrexed show
significant tumor growth delay in lung cancer cell lines.
Methods: Patients with non-small cell lung cancer, Eastern Coop-
erative Oncology Group performance status 0 to 1, who had received
one previous platinum containing regimen and normal organ func-
tion were treated with MGd 15 mg/kg and pemetrexed 500 mg/m2
q21days. Patients were allowed to receive more than one regimen if
the initial treatment was in the adjuvant or curative setting and
administered 12 months earlier. The primary end point was to
demonstrate a 40% rate of 6-month progression free survival (PFS).
Results: Seventy-two patients (30 women, 42 men), performance
status 0/1 (30/42), and a median age of 63 years were enrolled. Most
patients (96%) were current or former smokers. All histologic types
were represented (squamous/adenocarcinoma/other: 28%, 42%,
31%). Number of prior regimens: 1: 69%; 2: 26%, and 2: 4%.
Median number of cycles administered was (range) 2 (1–12). Tox-
icity: grade 3/4 neutropenia was noted in 8.3% with febrile neutro-
penia in 1.4%, thrombocytopenia in 8.3%, fatigue in 9.7%, and
pneumonia in 11.1%. There were no complete responses, 8.1% had
partial response, 56.5% had stable disease, and 35.5% had progres-
sive disease as their best response. Twenty-three percent of patients
were progression free at 6 months and the median PFS was 2.6
months with an overall survival of 8.1 months.
Conclusions: The combination of MGd and pemetrexed was well
tolerated with toxicity similar to that of pemetrexed alone. However,
the study did not achieve its end point of 40% 6-month PFS. The
response rate, PFS, and overall survival did not seem markedly
different than prior phase II and phase III studies of pemetrexed
alone. Consequently, there are no further plans for development of
this combination.
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(J Thorac Oncol. 2011;6: 786–789)
Three agents are currently approved for second-line ther-apy for non-small cell lung cancer (NSCLC) after initial
treatment with platinum-based combinations: docetaxel,
pemetrexed, and erlotinib. In a randomized trial, docetaxel
was improved survival compared with best supportive care
and was also demonstrated to be superior to other chemo-
therapy regimens (vinorelbine or ifosfamide) in terms of
response and landmark survival.1,2 Pemetrexed was shown to
be as effective as docetaxel in a randomized trial, with a
response rate of 9.1% compared with docetaxel of 8.8%.3 Both
agents had a median progression-free survival (PFS) of 2.9
months. Because of a lower incidence of most toxicities, partic-
ularly neutropenic fever and hospital admissions, pemetrexed is
now commonly used for second-line chemotherapy.
The investigational agent, motexafin gadolinium
(MGd), disrupts redox-dependent pathways by inhibiting ox-
idative stress-related proteins leading to apoptosis.4 MGd
selectively targets tumor cells, disrupting energy metabolism
and repair mechanisms, rendering cells more prone to apo-
ptosis with or without the addition of radiation and chemo-
therapy.5 Preclinical studies with MGd and radiation or a
wide range of chemotherapy agents including pemetrexed,
demonstrated significant tumor growth delay in lung cancer
cell lines, suggesting potential synergy between the two
drugs.6–10 Evidence from phase III trials suggests that there is
clinical benefit from the addition of MGd in addition to
radiation therapy in patients with metastatic NSCLC.11–13
Given the preclinical studies and evidence from clinical trials
of the potential efficacy of MGd in NSCLC and synergy with
pemetrexed, we designed this pilot phase II open-label trial to
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test the hypothesis that this combination would be both well
tolerated and improve outcome in the second line therapy for
NSCLC.
PATIENTS AND METHODS
Patient Population
To be eligible to participate in this study, a patient
should have been 18 years old and have a histologically or
cytologically confirmed diagnosis of stage IIIb/IV NSCLC.
Additionally, patients should have received one prior plati-
num-based chemotherapy regimen, have measurable disease
per RECIST, an Eastern Cooperative Oncology Group per-
formance status score of 0 or 1, no evidence of end-organ
dysfunction, and be willing and able to provide written
informed consent. Symptomatic or uncontrolled (untreated or
treated and progressing) brain metastases or evidence of
meningeal metastasis were also excluded. Patients were al-
lowed only one prior palliative cytotoxic regimen (not count-
ing adjuvant or neo-adjuvant cytotoxic chemotherapy if com-
pleted 12 months before the palliative regimen). Any prior
chemotherapy, radiation therapy, experimental therapy, im-
munotherapy, or systemic biologic anticancer therapy should
have ended at least 21 days before beginning study treatment,
and all toxicities related to the previous treatment must have
resolved or stabilized. Additional exclusionary criteria in-
cluded a known history of porphyria, glucose-6-phosphate
dehydrogenase deficiency, or HIV seropositivity, though test-
ing for these conditions was not required at the screening
visit, as well as any comorbidity, which interferes with the
ability to tolerate the protocol therapy assessments.
Treatment
MGd 15 mg/kg was administered once during the
first week of each 3-week cycle by intravenous infusion
over 60 minutes and given before pemetrexed 500 mg/m2
IV infused over 10 minutes. A maximum of 12 cycles of
treatment was permitted on this protocol. All patients
received folic acid 400 g/d starting 7 days before first
study treatment and continuing through 21 days after last
study treatment; vitamin B12 1 mg within 7 days before
first study treatment and on day 1 of cycles 4 and 8; and
dexamethasone 4 mg bid the day before, day of, and day
after each study treatment. Antiemetics were given at the
discretion of each investigator.
Objectives and Statistical Plan
The primary end point was 6-month PFS defined as the
time from first dose of MGd to the earlier of progression or
death. Patients who were still alive and who had not pro-
gressed by the time of their last response assessment were
censored at that time. PFS was plotted using the Kaplan-
Meier method. For the purposes of the sample size calcula-
tion, and based on the previous studies of docetaxel and
pemetrexed as single agents in this setting, a null PFS rate of
25% was assumed for 6-month PFS. An evaluable sample
size of 62 provided 80% power to reject the null hypothesis
of PFS of 25% when the true PFS rate is 40%. These
calculations were performed using the exact binomial test
with a two-sided alpha rate of 0.10.
Secondary objectives were time to progression, defined
as the time from the first dose of MGd to the first evidence of
progression, and overall survival. The patient population for
this end point consisted of all patients who received at least
1 dose of MGd and pemetrexed and underwent at least 1
response assessment. Patients who had not progressed by the
time of their last response assessment were censored at that
time. Time to progression and overall survival were deter-
mined using the Kaplan-Meier method.
Response, duration of response, and clinical benefit
ratio (complete response partial response stable disease)
were all determined using the RECIST.14 Toxicity was as-
sessed using the Common Terminology Criteria for Adverse
Events, version 3.0. The study was approved by the institu-
tional review board of each participating institution before
patient enrollment at that institution. All patients provided
written informed consent. The study was registered with
clinicaltrials.gov (NCT00365183).
RESULTS
The study opened on July 12, 2006, and completed
enrollment on August 26, 2008. A total of 72 patients en-
rolled and received at least one dose of therapy. Sixty-two
patients are evaluable for response. The demographics of the
study population are in Table 1. Of note, virtually all the
patients had significant history of tobacco use. Twenty-eight
percent had squamous cell carcinoma as this trial was com-
pleted before the observation that pemetrexed is preferen-
tially effective in adenocarcinoma.15 An exploratory analysis
did not demonstrate any benefits for that subset (median
survival for squamous versus nonsquamous, 244 versus 284
days, respectively). The combination was well tolerated with
an overall level of toxicity similar to that seen with pem-
etrexed as a single agent (Table 2). There were two grade 5
toxicities. In both patients, neutropenia and sepsis developed
after treatment. One patient, a 70-year-old man, developed
neutropenia and sepsis after the first course of therapy and
TABLE 1. Patient Demographics
Characteristic N
Age, median (range) 63 yr (37 – 83 yr)
Sex (M/F) 42/30
ECOG PS 0/1 30/42
Race
African American 6
White 66
Histology
Squamous/nonsquamous 20/52
Response to first-line therapy
No response 13
Response, TTP 3 mo 26
Response, TTP 3 mo 33
ECOG PS, Eastern Cooperative Oncology Group performance status; TTP, time to
progression.
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subsequently developed bowel obstruction, gastrointestinal
hemorrhage, and aspiration pneumonia leading to death. The
other patient, a 63-year-old woman, experienced neutropenic
sepsis and pneumonia after nine courses of pemetrexed and
motexafin and ultimately died of cardiogenic shock. Unfor-
tunately, the 6-month progression free survival, overall sur-
vival, response rate, clinical benefit ratio were also similar to
that which would be expected from pemetrexed as a single
agent (Table 3).
DISCUSSION
MGd is a tumor selective anticancer agent with a novel
mechanism of action. It has a strong affinity for electrons,
meaning that it is easily reduced.4 MGd accepts electrons
from various intracellular metabolites and enzymes, such as
ascorbate, NADPH, glutathione, and thioredoxin reductase in
the presence of oxygen, MGd transfers the electrons to
oxygen to produce reactive oxygen species, such as superox-
ide and hydrogen peroxide, and regenerates the MGd mole-
cule by a process referred to as “futile redox cycling.”16 MGd
is also able to oxidize protein thiols, which may alter protein
structure. As a result of these effects, MGd disrupts cellular
metabolism within the cancer cell, inhibiting DNA repair and
promoting apoptosis. In addition, MGd directly inhibits the
activity of thioredoxin reductase.5
MGd selectively accumulates in cancer cells, which has
been confirmed in vivo and in patients using magnetic reso-
nance imaging scanning to detect the biodistribution of the
paramagnetic, Gd (III)-containing complex.17 It is possible
that the tumor selectivity demonstrated by MGd is a conse-
quence of the altered redox state of these tissues or other
factors present in the tumor microenvironment, such as the
elevated rates of anaerobic glycolysis, a lowered tissue pH,
nutrient supply limitations, and hypoxia.
In preclinical models, MGd has been shown to be
cytotoxic to some lung cancer cell lines in vitro, both as a
single agent and in combination with various chemotherapy
drugs and radiation therapy. In A549 human lung cancer cells
cultured in vitro, MGd is cytotoxic after 12 hours incubation
at 50 M, a concentration achievable in humans. Because of
its multifunctional mechanism, cancer cells exposed to MGd
may be more vulnerable to many types of oxidative stress
including that caused by radiation therapy and chemothe-
rapy.7,18 As noted above, MGd has been shown to enhance
the in vitro and in vivo effects of a variety of chemothera-
peutic agents. The combination of MGd and pemetrexed was
studied in lung cancer cell lines both in tissue culture and in
an animal xenograft model and demonstrated synergy.6
The primary focus of MGd clinical development has
been as a tumor selective radiation enhancement agent.19,20 In
a randomized phase III trial of brain metastases (PCYC-
9801), a subset analysis demonstrated improved response,
prolonged time to neurologic and neurocognitive progression
and function in patients with brain metastases secondary to
NSCLC.12 Unfortunately, a phase III confirmatory interna-
tional study (PCYC-0211) confined to NSCLC brain metas-
tases failed to meet its predefined end point of prolonged time
to neurologic progression. However, in the intent-to-treat
analysis, MGd exhibited a favorable trend in neurologic
outcomes. MGd significantly prolonged the interval to neu-
rologic progression in NSCLC cancer patients with brain
metastases receiving prompt whole brain radiation therapy
and reduced the need for salvage brain surgery. The overall
negative result appeared to be attributable to an unexpected
influence of treatment delays in radiation therapy.13
MGd has been studied extensively in patients with lung
cancer. In a single dose phase I trial, the selective localization
of MGd in primary lung cancer, hilar lymph nodes, and other
metastatic sites was confirmed using magnetic resonance
imaging.19A phase II trial has evaluated MGd as a single
agent in progressive NSCLC with evidence of activity in the
form of disease stabilization.21 The experience combining
MGd with chemotherapy is much more limited. One prior
phase I trial combined the agent with docetaxel in advanced
solid tumors.22 A phase I trial restricted to NSCLC with
docetaxel and cisplatin and MGd demonstrated tolerability,
but there was no significant improvement of activity.23 Given
its excellent tolerability, tumor selectivity and preclinical
synergy with pemetrexed, evaluation in combination with
pemetrexed was a logical approach. However, despite the
ample preclinical data and previous observations demonstrat-
TABLE 2. Major Toxicities
Toxicity
Grade
3 4 5
Hematologic
Hemoglobin 8 0 0
Neutropenia 1 5 0
Thrombocytopenia 1 5 0
Febrile neutropenia 1 0 0
Nonhematologic
Gastrointestinal 7 0 0
Cardiac 3 1 0
Fatigue 6 1 0
Infection 9 0 2
TABLE 3. Response and Survival
Characteristic N
Response
Assessable 62
Not assessed 10
Best overall response
CR 0
PR 5
SD 35
PD 22
6-mo PFS (%) 23%
Progression-free survival, d 78
Median overall survival, d 244
1-yr survival (%) 36%
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; PFS, progression-free survival.
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ing single agent activity for MGd, there was no evidence of
benefit for this combination. It is possible that alternative
dosing schedules or combinations of other agents with MgD
could demonstrate some level of clinical benefit.
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